Amendment to Duties Addressing the Synthetic Opioid Supply Chain in the People's Republic of China
Signed: February 5, 2025
Published: February 11, 2025
Document Number: 2025-02512
📋Summary
This executive order changes a prior February 1, 2025 order that imposed new duties on certain covered imports tied to the synthetic opioid supply chain in China. It affects importers, shippers, and online sellers bringing these covered items into the United States, especially low-value shipments that might qualify for “de minimis” (duty-free) entry. For now, eligible covered items can still enter duty-free under the de minimis rule, but that duty-free treatment will end once the Secretary of Commerce tells the President that systems are ready to quickly process these shipments and collect the required tariff revenue. The order does not change agencies’ existing legal authorities, must be carried out within available funding, and does not create new enforceable rights for private parties.
💼Business Impact
This order keeps **de minimis (duty-free) entry under $800** available for covered China-origin articles subject to the opioid-supply-chain duties—but signals it may be **shut off once Commerce says systems can reliably assess and collect tariffs**, creating near-term uncertainty for import-dependent businesses. The most affected are **e-commerce sellers/marketplaces, drop-shippers, express carriers/3PLs, and retailers/manufacturers** sourcing small parcels or components from China that currently rely on de minimis to avoid duties and reduce paperwork. Businesses should prepare for a potential shift to **full tariff collection and more formal customs processing** (e.g., tighter product classification/origin documentation, broker usage, landed-cost recalculations), and may find opportunities in **diversifying sourcing, consolidating shipments, using FTZ/bonded strategies, or renegotiating supplier terms** to offset duty exposure. Immediate actions: **map SKUs and suppliers that enter via de minimis, model margin impact if duties apply, update pricing/checkout and customer terms for duty/tax pass-through, and coordinate with your customs broker/3PL to ensure data and entry processes are ready** if de minimis eligibility is withdrawn for these
Full Text
Executive Order 14200 of February 5, 2025
Amendment to Duties Addressing the Synthetic Opioid Supply Chain in the People's Republic of China
By the authority vested in me as President by the Constitution and the laws of the United States of America, including the International Emergency Economic Powers Act (50 U.S.C. 1701 et seq.), the National Emergencies Act (50 U.S.C. 1601 et seq.), section 604 of the Trade Act of 1974, as amended (19 U.S.C. 2483), and section 301 of title 3, United States Code, I hereby determine and order:
Section 1 . Amendment. Regarding the Executive Order of February 1, 2025 (Imposing Duties to Address the Synthetic Opioid Supply Chain in the People's Republic of China), the following shall replace subsection (g) of section 2:
“(g) Duty-free de minimis treatment under 19 U.S.C. 1321 is available for otherwise eligible covered articles described in subsection (a) of this section, but shall cease to be available for such articles upon notification by the Secretary of Commerce to the President that adequate systems are in place to fully and expediently process and collect tariff revenue applicable pursuant to subsection (a) of this section for covered articles otherwise eligible for de minimis treatment.”
Sec. 2 . General Provisions. (a) Nothing in this order shall be construed to impair or otherwise affect:
(i) the authority granted by law to an executive department, agency, or the head thereof; or
(ii) the functions of the Director of the Office of Management and Budget relating to budgetary, administrative, or legislative proposals.
(b) This order shall be implemented consistent with applicable law and subject to the availability of appropriations.
( printed page 9278)(c) This order is not intended to, and does not, create any right or benefit, substantive or procedural, enforceable at law or in equity by any party against the United States, its departments, agencies, or entities, its officers, employees, or agents, or any other person.
THE WHITE HOUSE,
February 5, 2025.